Vimta Labs Thrives
Vimta Labs Reports Q1 FY27 Profit Up 11.4%, Income Rises 13.7% on Expansion
Anonymous
Key Points
1
Q1 FY27 EBITDA stood at ₹411 million with a margin of 36.4%, up 16% YoY from ₹354 million in Q1 FY26, though down slightly from ₹421 million in the previous quarter.
2
Vimta commenced operations in Biologics Contract Research and Development Services (CRADS) during Q1 FY27, expanding its high-margin service portfolio.
3
PAT margin declined to 18.6% in Q1 FY27 from 19.0% a year earlier, even as net profit rose 11.4% to ₹210 million.
4
Total income for the quarter was ₹112.89 crore (₹1,128.86 million), up 13.7% YoY, with ₹3.81 crore of other income contributing to the mix.
5
During the quarter, Vimta granted 40,500 stock options under its VLESOP-2021 plan to employees, reflecting ongoing talent and incentive initiatives.
Vimta Labs posted a strong first quarter for FY27, with net profit climbing 11.4% year on year to ₹210.42 million, according to Sahi. Total income rose 13.7% to ₹1,128.86 million, driven by double-digit gains across both top-line and bottom-line metrics.
The contract research and testing company also launched a new high-margin service line during the quarter. Vimta commenced operations in Biologics Contract Research and Development Services, known as CRADS, marking a significant step in its growth strategy, TradingView reported.
EBITDA Hits ₹411 Million With 36% Margin
Vimta's EBITDA for Q1 FY27 reached ₹411 million, up 16% from ₹354 million in the same quarter last year, according to TradingView. The EBITDA margin came in at 36.4%, showing strong operating efficiency even as the company invests in new services.
Revenue from operations stood at ₹1,090.74 million for the quarter, Sahi reported. Other income added ₹38.1 million to the mix, bringing total income to ₹1,128.86 million. The PAT margin eased slightly to 18.6% from 19.0% a year ago, even as absolute profit grew.
Biologics CRADS Launch Opens High-Margin Door
The start of Biologics CRADS operations is a key development for Vimta. Biologics are complex, large-molecule drugs. Contract research and development for them tends to command higher fees than standard testing work. This move broadens Vimta's service mix beyond traditional pharmaceutical testing.
TradingView noted that management pointed to momentum in Pharmaceutical Research and Testing Services as a core growth driver. The company is also deepening its push into domestic markets while exploring new ventures, including a US subsidiary and public-private partnerships.
Ukraine Audit and Quality Milestones Boost Credibility
During the quarter, Vimta completed a regulatory audit in Ukraine, according to TradingView. Management cited the successful audit as proof of its quality standards. Passing such reviews is critical for labs that serve global pharmaceutical clients who need regulators to approve their supply chains.
The company also granted 40,500 stock options to employees under its VLESOP-2021 plan, Scanx Trade reported. The move signals Vimta's focus on retaining talent as it scales up. Keeping skilled staff is especially important as the company enters technically demanding areas like biologics research.
Profit Rises Despite Margin Pressure From Inflation
Net profit grew to ₹210.42 million in Q1 FY27 from ₹188.94 million a year ago, Scanx Trade reported. That is an 11.4% jump. However, the PAT margin dipped slightly. This suggests rising costs — likely from inflation and new service investments — are eating into a small slice of earnings.
Still, the overall picture is healthy. EBITDA margins near 36% and double-digit profit growth show Vimta is managing costs well. TradingView noted that the company is positioned for sustained growth through FY27 as it expands its portfolio and client base.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
12
Articles
1
Reach
13
Topics
A
AnonymousAuthor